Prescribing overview
Lotensin is human-labeled for hypertension. Veterinary use of this product requires an extra-label prescription; no animal regimen was verified from its human label.
Key prescribing checks
- The human label emphasizes blood-pressure, renal-function and potassium monitoring. These are important screening topics for the prescribing veterinarian, especially with dehydration or concurrent diuretics.
- NSAIDs and other agents affecting the renin–angiotensin system can increase renal or hypotension risk. Review all prescription drugs and supplements rather than matching the brand alone.
- The human label includes a fetal-toxicity warning and hypersensitivity/angioedema contraindications. Human dosing and human indication wording are not veterinary instructions.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Veterinary patients
Extra-label for the cited human productPatient-specific cardiovascular/renal treatment selected by veterinarian
Human hypertension approval does not establish a veterinary indication.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Benazepril is converted to benazeprilat, which inhibits ACE and reduces angiotensin-II formation and aldosterone secretion.
Absorption, distribution, metabolism and elimination
The cited label describes human metabolism and elimination. Species-specific veterinary quantitative pharmacokinetics were not verified and human values are not extrapolated.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Lotensin
Human benazepril tablet label; not established veterinary prescribing guidance.
Contraindications · when not to use
- Benazepril/ACE-inhibitor hypersensitivity or angioedema history; neprilysin-inhibitor combination, including the specified sacubitril transition interval; aliskiren coadministration in diabetes.
Precautions & monitoring
- Boxed fetal-toxicity warning; renal impairment, hypotension and hyperkalemia require monitoring.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human-label risks include hypotension, renal impairment, hyperkalemia and angioedema; animal incidence is not established by this source.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
Veterinary dose not verified from an approved veterinary label. Do not copy the human dose or renal-adjustment table.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Lotensin
Human benazepril tablet label; not established veterinary prescribing guidance.
- NSAIDs, diuretics, potassium-raising drugs, other RAS inhibitors, lithium and mTOR inhibitors may increase toxicity or require monitoring.
Monitoring
Veterinarian-directed blood pressure, renal function, hydration and potassium assessment; review NSAIDs, diuretics and potassium-raising drugs.
Client counseling
Report collapse, marked weakness or facial swelling; do not adjust treatment without the prescriber.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Keep in the original labeled container under its product-specific conditions; distinguish single-ingredient from combination tablets.
Brands, formulations & ingredient identity
Active ingredients
Benazepril
Other searchable names: Benazepril hydrochloride
Lotensin contains benazepril hydrochloride. The base drug and salt spelling both help identify the same active moiety.
Do not assume a product carrying an additional brand suffix has only benazepril. Check the complete active-ingredient panel, strength and formulation before reconciling a prescription.
Record both the ingredient and the actual dispensed product so future refills preserve the intended preparation.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Lotensin
- Formulation
- Oral tablets
- Label / product scope
- Human product
Human-labeled benazepril product; veterinary approval is not implied.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →